Olema Pharmaceuticals (NASDAQ: OLMA) — Company Overview, News & Financial Data
Olema Pharmaceuticals focuses on targeted therapies for women's cancers, advancing OP-1250 for breast and hormone-driven cancers.
Olema Pharmaceuticals
Olema Pharmaceuticals (NASDAQ:OLMA) is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. With a deep commitment to addressing unmet medical needs, their primary project revolves around advancing their lead candidate, OP-1250, a novel therapy in clinical trials aiming at both the treatment of breast cancer and other hormone-driven cancers. Through groundbreaking research and a dedicated team, Olema is striving to bring innovative solutions from the laboratory to patients, aiming to improve outcomes and quality of life for those facing these challenging diagnoses. Their objective is not only to pioneer advancements in the oncology field but also to establish a legacy of contributing significant breakthroughs in cancer care.
Snapshot
Operations
Products and/or services of Olema Pharmaceuticals
- OP-1250, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) for metastatic breast cancer treatment.
- Investigation of OP-1250 in combination therapies for broader efficacy in cancer treatment, exploring synergies with established cancer therapies.
- Development of next-generation SERDs aimed at overcoming resistance to current therapies and providing new options for hormone receptor-positive breast cancer.
- Expansion into targeted therapies for other hormonally driven cancers, leveraging the technology platform behind OP-1250.
- Preclinical studies on novel oncology targets, identifying promising compounds for future pipeline expansion.
- Collaborations with academic and industry partners to accelerate the development of its oncology portfolio and share expertise.
Olema Pharmaceuticals executive team
- Sean P. BohenPresident, CEO & Director
- Shawnte M. MitchellChief Legal Officer & Corporate Secretary
- Jason O'ByrneCFO, Principal Financial Officer & Accounting Officer
- David C. MylesChief Scientific Officer
- Courtney O'KonekVice President of Corporate Communications
- Julie DexterSenior VP & Head of People
- Naseem ZojwallaChief Medical Officer
- Richard HernandezSenior Vice President of Clinical Development Operations
- Mark ShilkrutSenior Vice President of Clinical Development
- Kamesh KuchimanchiSenior Vice President of Regulatory Affairs & Quality Assurance
Latest news about Olema Pharmaceuticals
Key financials
Reported results for Olema Pharmaceuticals, in USD.
- Market cap
- 655.4M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -2.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -178.7M | -162.5M | |
| 0 | -142.3M | -129.5M | |
| 0 | -105M | -96.7M | |
| 0 | -107M | -102.6M |